Tech Company Inital Public Offerings
Sienna Biopharmaceuticals IPO
Sienna Biopharmaceuticals, based in Westlake Village, debuted as a public company on 7/27/2017.
Transaction Overview
Company Name
Announced On
7/27/2017
Transaction Type
IPO
Amount
$64,500,000
Proceeds Purpose
We currently expect to use our net proceeds from this offering, together with our existing cash, as follows: approximately $27.0 million to fund the clinical development of SNA-120 through top-line results in our Phase 2b trial; approximately $7.0 million to fund our preclinical and clinical studies for SNA-125 through receipt of proof of concept data in each of atopic dermatitis and psoriasis; approximately $20.0 million to fund our ongoing pivotal clinical trials for SNA-001 through receipt of top-line results; and the balance to fund internal research and development expenses and for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
30699 Russell Ranch Rd. 140
Westlake Village, CA 91362
USA
Westlake Village, CA 91362
USA
Phone
Website
Email Address
Not Recorded
Overview
Sienna Biopharmaceuticals (NASDAQ: SNNA) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians' practice of medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frederick Beddingfield
Chief Financial Officer
John Smither
Chief Medical Officer
Paul Lizzul
Chief Scientific Officer
Silvio Traversa
Vice President
Debra Condino
VP - Bus. Development
Todd Harris
VP - Bus. Development
Caroline Hove
VP - General Counsel
Timothy Andrews
VP - Operations
Majed Kheir
VP - Regulatory Affairs
Ryan Irvine
VP - Regulatory Affairs
Diane Stroehmann
Browse more venture capital transactions:
Prev: 7/27/2017: Aiqudo venture capital transaction
Next: 7/28/2017: Callsign venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs